首页> 美国卫生研究院文献>Journal of Pathogens >Antimicrobial Susceptibility among Colistin Sulbactam and Fosfomycin and a Synergism Study of Colistin in Combination with Sulbactam or Fosfomycin against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii
【2h】

Antimicrobial Susceptibility among Colistin Sulbactam and Fosfomycin and a Synergism Study of Colistin in Combination with Sulbactam or Fosfomycin against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii

机译:ColistinSulbactam和磷霉素之间的抗菌药敏性以及Colistin与Sulbactam或磷霉素的协同作用对耐碳青霉烯类鲍曼不动杆菌的临床分离株的协同作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This in vitro study aimed to determine the activity of colistin plus sulbactam and colistin plus fosfomycin against carbapenem-resistant A. baumannii (CRAB). Fifteen clinical isolates were obtained from patients admitted to Phyathai II International Hospital, Bangkok, Thailand, from August 2014 to April 2015. The antimicrobial susceptibilities of colistin, sulbactam, and fosfomycin were evaluated using the E-test or broth microdilution and the synergistic activity of the antibacterial combinations (colistin plus sulbactam or fosfomycin) was determined using the chequerboard method. Clonal relationships were explored using repetitive element palindromic- (REP-) PCR. The CRAB isolates were categorized by REP-PCR in 8 groups [A-H]. All CRAB isolates were universally susceptible to colistin but only 20.0% were susceptible to sulbactam. The MIC ranges for colistin, sulbactam, and fosfomycin were 0.75–2 mg/L, 2–96 mg/L, and 64–256 mg/L, respectively. A chequerboard assay revealed that the rates of synergistic and additive effect rates of colistin plus sulbactam and colistin plus fosfomycin were 53.3% and 73.3% of isolates, respectively. No antagonistic effect in any colistin-based combination was observed. However, almost CRAB strains in clone A showed the synergy or additive effects of colistin-sulbactam combination, whereas the other clone (B-H) mostly showed indifferent effects. In conclusion, colistin plus sulbactam and colistin plus fosfomycin against CRAB seem to be interesting option but the efficacy in clinical use has to be evaluated.
机译:这项体外研究旨在确定粘菌素加舒巴坦和粘菌素加磷霉素对耐碳青霉烯的鲍曼不动杆菌的活性。从2014年8月至2015年4月,从泰国曼谷Phyathai II国际医院收治的患者中获得了15株临床分离株。大肠菌素,舒巴坦和磷霉素的抗菌药敏性通过E检验或肉汤微稀释度进行了评估,并具有协同作用。抗菌组合(colistin加舒巴坦或磷霉素)的测定采用棋盘法。使用重复元素回文-(REP-)PCR探索了克隆关系。通过REP-PCR将CRAB分离物分为8组[A-H]。所有CRAB分离株普遍对粘菌素敏感,但只有20.0%对舒巴坦敏感。大肠菌素,舒巴坦和磷霉素的MIC范围分别为0.75–2μmg / L,2-96μmg/ L和64–256μmg / L。棋盘实验表明,大肠菌素加舒巴坦和大肠菌素加磷霉素的协同作用和加和作用率分别为分离株的53.3%和73.3%。在任何基于大肠杆菌素的组合中均未观察到拮抗作用。但是,克隆A中几乎所有CRAB菌株都表现出大肠菌素-舒巴坦组合的协同作用或累加作用,而其他克隆(B-H)则大多表现出不同的作用。总之,针对CRAB的大肠菌素加舒巴坦和大肠菌素加磷霉素似乎是有趣的选择,但必须评估其临床使用效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号